Ann: Compelling 85% Success Rate Remplir Study now published, page-9

Apparently not @KainCarver I don;t know what this company needs to do to gain Aussie investor interest. Literally rescues AFL players from tendon injury forced retirement and they come back to have their best seasons ever. If ATI not attractive enough, grants independence to quadriplegic patients by restoring arm function so they can have quality of life unimaginable to them prior and announces fantastic rates of success in surgeries that many surgeons wouldn't go near with sutures.

Even if investors ignore the sheer number of nerve injuries globally a year (PNI damage typically effects 15-25 per 100,000 people a year so crude math gives you 1.2 to 2 million a year globally) they could think of the sheer number of existing quadriplegic people globally this could potentially help.

Its been on national TV, in peer reveiewed journals, has announced a Fortune 500 company deal in a sideline that is a smidgin of the sales potential in other applications for Remplir in its already FDA approved Striate. The sales from the BH/HS deals are growing steadily. Sure the marketing and sales dept. a bit weak, but the potential of this company is huge. Its like the mkts are stupid. They really do lack imagination on forward earnings potential and pricing. Hence I suppose you could have bought Fortiscue for less then a tenth of the price it is now in 2016. Or Nividia for a hundred times less than it is now.

(I held both and sold out at far lower mulitples - needed the money at the time - but I won't make the same mistake in OCC).